Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 121,300 shares, an increase of 46.5% from the October 15th total of 82,800 shares. Based on an average daily trading volume, of 145,700 shares, the short-interest ratio is presently 0.8 days. Currently, 4.8% of the shares of the stock are short sold.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $19.58 on Thursday. The firm has a market cap of $62.66 million, a PE ratio of -1.46 and a beta of 2.11. The firm’s fifty day moving average is $9.95 and its 200-day moving average is $12.46. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The company had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. During the same period in the prior year, the business earned ($10.25) earnings per share. Sell-side analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALGS. Acadian Asset Management LLC lifted its position in shares of Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the period. Opaleye Management Inc. raised its stake in Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after buying an additional 333,000 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the period. 60.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).